TGFB1 and Marfan syndrome: However, a multicenter clinical trial involving patients with MFS revealed no significant impact from inhibiting the TGFB mediated canonical SMAD2-SMAD3 cascade through the administration of the AGTR (angiotensin II receptor) blocker losartan.